文献速递免疫规划卫生政策与健康促进

芬兰婴儿普种乙肝疫苗项目的成本效果分析

Cost-effectiveness of universal infant hepatitis B vaccination programme in Finland.
PubMed 文献 · Vaccine · 2026-10-16

该研究采用静态队列模型,比较芬兰婴儿普种乙肝疫苗与现行针对性接种项目的医疗成本与健康效果。基于国家登记数据估算,在58,000名儿童出生队列中,普种项目的增量成本效果比(ICER)在五价与六价疫苗每剂价差2至12欧元时为24,500至162,900欧元/QALY。结论认为,在乙肝极低流行国家,仅当五价与六价疫苗价差极小时普种项目才具成本效果。

要点

  • 芬兰婴儿普种乙肝疫苗的ICER随五价与六价疫苗价差增大而升高。
  • 结果对乙肝发病率、疫苗成本和贴现率敏感。
  • 在乙肝极低流行国家,仅价差极小时普种项目才具成本效果。

核心结论

  • 在芬兰这类乙肝极低流行国家,婴儿普种乙肝疫苗项目仅在五价与六价疫苗价差极小时才可视为对公共卫生资源的合理使用。

研究设计与样本

  • 采用静态队列模型,比较婴儿普种乙肝疫苗接种项目与现行针对性接种项目的医疗成本与健康效果。
  • 乙肝发病率和相关成本估算来自国家登记数据,并考虑了急性无症状感染。
  • 对成本和健康效果采用3%的年贴现率,主要结局指标为每获得一个质量调整生命年(QALY)的成本。

主要发现

  • 在58,000名儿童出生队列中,估算有41例急性乙肝病例(每5例中1例有症状)、3例慢性乙肝病例和3例乙肝相关死亡。
  • 对应的医疗成本为46,400欧元,损失14.4个QALY。
  • 当五价与六价疫苗每剂价差在2至12欧元之间时,增量成本效果比(ICER)为24,500至162,900欧元/QALY。
  • 结果对乙肝发病率、疫苗成本和贴现率敏感。

关键数值与推荐

  • 五价与六价疫苗每剂价差2至12欧元时,ICER为24,500至162,900欧元/QALY。
  • 成本和健康效果的年贴现率为3%。

临床怎么用

  • 在乙肝极低流行国家决策婴儿普种乙肝疫苗时,应重点评估五价与六价疫苗的价差。
  • 需结合本地乙肝发病率、疫苗成本和贴现率进行敏感性分析。

局限性

  • 研究采用静态队列模型,可能未完全捕捉动态传播效应。
  • 结果基于芬兰国家登记数据,外推至其他地区需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the cost-effectiveness of a universal infant hepatitis B vaccination programme in Finland. METHODS: A static cohort model was employed to compare the health care costs and health effects of a universal infant hepatitis B vaccination programme with the present targeted vaccination programme. Estimates of hepatitis B incidence and hepatitis B-related costs were derived from national register data. The estimated hepatitis B incidence took into account acute asymptomatic infections. An annual discount rate of 3% was applied to costs and health effects and the main outcome measure was cost per quality adjusted life year (QALY) gained. We present the results with different price differences per dose of hexavalent and pentavalent vaccines. Sensitivity analyses identified influential inputs in the cost-effectiveness analysis. RESULTS: We estimated 41 acute cases with every fifth being symptomatic, three chronic hepatitis B cases, and three hepatitis B-related deaths in a birth cohort of 58,000 children. The corresponding health care costs were ϵ46,400 and QALYs lost 14.4. The incremental cost-effectiveness ratios (ICER) were between ϵ24,500 and ϵ162,900 when the price difference per dose of pentavalent versus hexavalent vaccine was between two and 12 euros. The results were sensitive to hepatitis B incidence, vaccine cost, and discount rate. CONCLUSIONS: In a very low hepatitis B prevalence country such as Finland, a universal infant hepatitis B vaccination programme appears justifiable use of public health care resources only with a very small price difference between pentavalent and hexavalent vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nieminen T, Nurhonen M, Leino T, et al. Cost-effectiveness of universal infant hepatitis B vaccination programme in Finland. Vaccine. 2026. PMID: 42887417. doi:10.1016/j.vaccine.2026.129171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。